Source comparison
Comparison: Daily vs Intermittent Thymosin Alpha-1 Protocols
Before selecting a dosing schedule, compare the clinical evidence, cost implications, and practical considerations across administration frequencies. Daily 0.9mg (7×/week) 6.3mg IL-2 elevation sustained; CD4+ count +12–18% from baseline at 4 weeks Injection si
This comparison does not assign a generated winner or score.
- Before selecting a dosing schedule, compare the clinical evidence, cost implications, and practical considerations across administration frequencies.
- Daily 0.9mg (7×/week)
- 6.3mg
- IL-2 elevation sustained; CD4+ count +12–18% from baseline at 4 weeks
- Injection site reactions 8–12%; mild fatigue 5–8%
- $420–$560 (assuming $2/mg)
- Highest peptide consumption; minimal efficacy gain over intermittent dosing in most contexts. Reserve for profoundly immunosuppressed populations or mechanistic studies requiring stable plasma levels.
- Daily 1.6mg (7×/week)
- 11.2mg
- IL-2 elevation sustained; CD4+ count +18–24%; NK cytotoxicity +22–30%
- Injection site reactions 10–14%; mild fatigue 6–10%; rare transient fever <2%
- $740–$980
- Used in oncology trials for chemotherapy patients. Produces strong immune response but at double the peptide cost of twice-weekly protocols with comparable clinical endpoints (infection rates, tumor response).
- Twice-weekly 1.6mg (e.g., Mon/Thu)
- 3.2mg
- IL-2 elevation intermittent but returns to near-baseline; CD4+ count +10–16%; NK cytotoxicity +18–25%
- Injection site reactions 6–9%; mild fatigue 3–5%
- $210–$280
- Standard protocol in hepatitis B/C, HIV, and sepsis trials. Most cost-effective with strongest clinical trial support. Balances immune activation with peptide economy.
- Thrice-weekly 1.6mg (e.g., Mon/Wed/Fri)
- 4.8mg
- IL-2 elevation more sustained than twice-weekly; CD4+ count +14–20%; NK cytotoxicity +20–28%
- Injection site reactions 7–11%; mild fatigue 4–7%
- $315–$420
- Middle-ground approach. Some oncology protocols use this frequency during active treatment phases. Slightly better immune marker elevation than twice-weekly, but marginal benefit relative to 50% cost increase.
- The bottom line: unless you're working with a population where immune suppression is so severe that intermittent signaling fails to sustain response, twice-weekly 1.6mg protocols deliver the best balance of efficacy, safety, and cost.